HomeInsightsStock Comparison

Ipca Laboratories Ltd vs Morepen Laboratories Ltd Stock Comparison

Ipca Laboratories Ltd vs Morepen Laboratories Ltd Stock Comparison

Last Updated on: Jun 02, 2025

Key Highlights

  • The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1399 as of 02 Jun 16:01.
  • The P/E Ratio of Ipca Laboratories Ltd changed from 28.9 on March 2020 to 57.4 on March 2024 . This represents a CAGR of 14.71% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 22.4 on March 2024 . This represents a CAGR of 12.02% over 5 years.
  • The Market Cap of Ipca Laboratories Ltd changed from ₹ 17538 crore on March 2020 to ₹ 31414 crore on March 2024 . This represents a CAGR of 12.36% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore on March 2020 to ₹ 2149 crore on March 2024 . This represents a CAGR of 38.03% over 5 years.
  • The revenue of Ipca Laboratories Ltd for the Mar '25 is ₹ 2272 crore as compare to the Dec '24 revenue of ₹ 2265 crore. This represent the growth of 0.31% The revenue of Morepen Laboratories Ltd for the Mar '25 is ₹ 470.46 crore as compare to the Dec '24 revenue of ₹ 458.12 crore. This represent the growth of 2.69%.
  • The ebitda of Ipca Laboratories Ltd for the Mar '25 is ₹ 249.63 crore as compare to the Dec '24 ebitda of ₹ 483.19 crore. This represent the decline of -48.34% The ebitda of Morepen Laboratories Ltd for the Mar '25 is ₹ 46.85 crore as compare to the Dec '24 ebitda of ₹ 41.48 crore. This represent the growth of 12.95%.
  • The net profit of Ipca Laboratories Ltd changed from ₹ 166.21 crore to ₹ 65.78 crore over 8 quarters. This represents a CAGR of -37.09% The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 20.31 crore over 8 quarters. This represents a CAGR of 17.82% .
  • The Dividend Payout of Ipca Laboratories Ltd changed from 9.68 % on March 2020 to 19.13 % on March 2024 . This represents a CAGR of 14.60% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ipca Laboratories Ltd

  • Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
  • The products of the Company are now sold in over 100 countries across the globe.
  • The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

Ipca Laboratories Ltd News Hub

News

Board of Ipca Laboratories recommends final dividend

Ipca Laboratories announced that the Board of Directors of the Company at its meeting held...

Read more

29 May 2025 14:29

News

Ipca Laboratories to announce Quarterly Result

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2...

Read more

15 May 2025 15:38

News

Ipca Laboratories now holds 100% stake in Unichem Laboratories, Ireland

Ipca Laboratories announced that 100% of the paid-up equity share capital of Unichem Labor...

Read more

02 May 2025 11:27

News

Ipca Laboratories appoints President - Human Resources

Ipca Laboratories has appointed Saidutta Nanda as President - Human Resources of the compa...

Read more

03 Mar 2025 16:06

News

Ipca Laboratories Ltd down for fifth straight session

Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at ...

Read more

28 Feb 2025 13:35

News

Ipca Labs spurts after Q3 PAT soars to Rs 267 cr

Revenue from operations jumped 10.34% YoY to Rs 1,662.68 crore in the quarter ended 31st D...

Read more

13 Feb 2025 15:03

Morepen Laboratories Ltd News Hub

News

Board of Morepen Laboratories approves availing of working capital loan of Rs 50 cr

The Board of Morepen Laboratories at its meeting held on 23 May 2025 has approved inter-al...

Read more

23 May 2025 10:25

News

Board of Morepen Laboratories notes incorporation of step-down subsidiary in Dubai

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decisio...

Read more

12 May 2025 18:29

News

Board of Morepen Laboratories recommends Final Dividend

Morepen Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

12 May 2025 16:11

News

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 Ma...

Read more

06 May 2025 11:55

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

News

Morepen Laboratories launches four new products for domestic market

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, ...

Read more

24 Apr 2025 16:13

SWOT Analysis Of Ipca Laboratories Ltd

Strength

2

S

Weakness

4

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ipca Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ipca Laboratories Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Morepen Laboratories Ltd?

Market cap of Ipca Laboratories Ltd is 36,126 Cr while Market cap of Morepen Laboratories Ltd is 3,551 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Morepen Laboratories Ltd?

The stock performance of Ipca Laboratories Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Morepen Laboratories Ltd?

As of June 2, 2025, the Ipca Laboratories Ltd stock price is INR ₹1423.95. On the other hand, Morepen Laboratories Ltd stock price is INR ₹64.82.

How do dividend payouts of Ipca Laboratories Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions